Navigation Links
Glivec the hot cancer drug from Novartis

Novartis is the world's sixth-largest drugmaker (by sales).
Novartis was formed after merger of two Swiss companies, Sandoz Ltd. and Ciba-Geigy."Novartis is emerging as one of the premier powerhouses in the global pharmaceuticals industry," says Richard R. Stover, senior analyst with brokerage Natexis Bleichroeder Inc. in New York. The new cancer drug, Glivec's success led to Novartis reported a 24% jump in first-quarter operating earnings, to $1.4 billion, on sales of $5.7 billion. The stock has climbed 15% since mid-March and continues to outperform the industry.

Glivec was first approved for treatment of chronic myeloid leukemia. It is the first treatment ever proven drug to cause certain types of tumors to disappear. While other cancer drugs killsoff healthy cells along with sick ones, Glivec interfere with the proteins that cause tumors to grow. Glivec also is used to treat other rare types of cancer such as gastrointestinal stromal tumors (GIST) and is now being tested in combination with other drugs in fighting prostate cancer.

Glivec was introduced in the U.S. in 2001 under the brand name Gleevec. Sales rose more than 300% in 2002, and could hit the $1 billion mark by the end of this year. Although an annual course of Glivec can cost as much as $25,000, demand for the drug took off so quickly that Novartis was forced to run its production line around the clock.

Since the year 2000 Novartis has launched 10 drugs and this is three times more than its nearest rival. Another 15 are expected to debut by 2006. Among the current crop are Zelmac, a drug for irritable-bowel syndrome;eczema treatment Elidel; and Zometa, a treatment for bone metastases.
'"/>




Page: 1

Related medicine news :

1. Glivec - New Hope For CMC Patients
2. Glivec Enhances Survival Rates In Leukemia
3. Vitamin B12 can help in detecting cancers
4. Want skin cancer? Please have a cigarette
5. New hope for cancer victims – will vaccine cure the deadly bug
6. Clintons new problem - Is the outgoing American president suffering from skin cancer?
7. Are cancer patients being taken for a ride?
8. Breast cancer treatment to be determined by gene test
9. Ductal lavage may detect early breast cancer
10. Beware of the oral patch! It could be cancer!!!
11. New drug helps boost cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... ... Patel M.D. has joined the revolutionary endoscopic practice under Dr. Datta. Patel is ... Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), ... labor and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding ... the hospital and decide to donate. , “Women’s Hospital at Renaissance has been ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
(Date:4/28/2017)... ... 2017 , ... Bill Howe started his sewer and drain company in 1980 ... joined the team, the Bill Howe brand was born and they began cultivating their ... back to the San Diego community in which they worked, lived and were raising ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: